JP4808154B2 - プロテインキナーゼインヒビターとして有用な組成物 - Google Patents
プロテインキナーゼインヒビターとして有用な組成物 Download PDFInfo
- Publication number
- JP4808154B2 JP4808154B2 JP2006507111A JP2006507111A JP4808154B2 JP 4808154 B2 JP4808154 B2 JP 4808154B2 JP 2006507111 A JP2006507111 A JP 2006507111A JP 2006507111 A JP2006507111 A JP 2006507111A JP 4808154 B2 JP4808154 B2 JP 4808154B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- compounds
- compound
- protein kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QLAIETCXQIBVIO-UHFFFAOYSA-N CC(C)Nc1nc(-c2c(C)[nH]c(C(NCCO)=O)c2C)c(CO)cn1 Chemical compound CC(C)Nc1nc(-c2c(C)[nH]c(C(NCCO)=O)c2C)c(CO)cn1 QLAIETCXQIBVIO-UHFFFAOYSA-N 0.000 description 1
- AZHMXENTEHSRDO-UHFFFAOYSA-N CCC(C1)(C1O)Nc1nc(-c2c(C)[nH]c(C(NCCO)=O)c2C)c(CO)cn1 Chemical compound CCC(C1)(C1O)Nc1nc(-c2c(C)[nH]c(C(NCCO)=O)c2C)c(CO)cn1 AZHMXENTEHSRDO-UHFFFAOYSA-N 0.000 description 1
- GYZAEFXCAJCBGT-UHFFFAOYSA-N Cc1c(C(NCCO)=O)[nH]c(C)c1-c1ccnc(N2CCOCC2)n1 Chemical compound Cc1c(C(NCCO)=O)[nH]c(C)c1-c1ccnc(N2CCOCC2)n1 GYZAEFXCAJCBGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45440503P | 2003-03-13 | 2003-03-13 | |
| US60/454,405 | 2003-03-13 | ||
| PCT/US2004/007540 WO2004083203A1 (en) | 2003-03-13 | 2004-03-11 | Compositions useful as protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520386A JP2006520386A (ja) | 2006-09-07 |
| JP2006520386A5 JP2006520386A5 (cg-RX-API-DMAC10.html) | 2007-05-10 |
| JP4808154B2 true JP4808154B2 (ja) | 2011-11-02 |
Family
ID=33029879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507111A Expired - Fee Related JP4808154B2 (ja) | 2003-03-13 | 2004-03-11 | プロテインキナーゼインヒビターとして有用な組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7456190B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1606284B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4808154B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE450530T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2004221881A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2522176A1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE602004024374D1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004083203A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1751133B1 (en) * | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1833820A1 (en) * | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
| FR2881742B1 (fr) * | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
| UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
| EP1942897A1 (en) * | 2005-10-03 | 2008-07-16 | AstraZeneca AB | Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Erkインヒビターとしてのピロリジン誘導体 |
| CA2649302A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | Anilino-pyrimidine phenyl and benzothiophene analogs |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| CN102015693B (zh) | 2008-02-21 | 2014-10-29 | 默沙东公司 | 作为erk抑制剂的化合物 |
| WO2010060088A2 (en) * | 2008-11-24 | 2010-05-27 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| US20100136096A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100136095A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100135908A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Delivery devices for modulating inflammation |
| US20100135984A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100137246A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| EP2419425A4 (en) | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| WO2017096233A1 (en) | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| WO2021195360A1 (en) * | 2020-03-27 | 2021-09-30 | Landos Biopharma, Inc. | Plxdc2 ligands |
| WO2025264278A1 (en) * | 2024-06-18 | 2025-12-26 | Memorial Sloan-Kettering Cancer Center | Erk2 degraders |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1311336A (en) * | 1970-09-07 | 1973-03-28 | Ici Ltd | Quaternary salts of pyrolylpyridine derivatives |
| WO1995018122A2 (en) * | 1993-12-30 | 1995-07-06 | Ciba-Geigy Ag | Heteroarylpyrroles |
| WO1996040634A1 (en) * | 1995-06-07 | 1996-12-19 | Nippon Shinyaku Co., Ltd. | Pyrrole derivatives and medicinal composition |
| WO1997016426A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| JPH10324687A (ja) * | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
| JP2000514808A (ja) * | 1997-06-16 | 2000-11-07 | ファイザー製薬株式会社 | インターロイキン―およびtnfアンタゴニストとして有用なピリジルピロール化合物 |
| JP2001247564A (ja) * | 1999-07-21 | 2001-09-11 | Sankyo Co Ltd | ヘテロアリール置換ピロール誘導体 |
| WO2002064586A2 (en) * | 2001-02-09 | 2002-08-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of erk2 and uses thereof |
| JP2002284780A (ja) * | 2001-01-22 | 2002-10-03 | Sankyo Co Ltd | 4又は5置換ピロール誘導体 |
| WO2002079193A1 (en) * | 2001-03-29 | 2002-10-10 | Cyclacel Limited | Inhibitors of cyclin dependent kinases as anti-cancer agent |
| JP2002544272A (ja) * | 1999-05-14 | 2002-12-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換3−ピリジル−4−アリールピロール並びに関連した治療及び予防法 |
| WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| WO2004029040A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases |
| WO2004056368A1 (en) * | 2002-12-19 | 2004-07-08 | Cyclacel Limited | Therapeutic applications of 2-substituted 4-heteroarylryrimidines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
-
2004
- 2004-03-11 US US10/798,766 patent/US7456190B2/en not_active Expired - Fee Related
- 2004-03-11 CA CA002522176A patent/CA2522176A1/en not_active Abandoned
- 2004-03-11 AU AU2004221881A patent/AU2004221881A1/en not_active Abandoned
- 2004-03-11 EP EP04719833A patent/EP1606284B1/en not_active Expired - Lifetime
- 2004-03-11 JP JP2006507111A patent/JP4808154B2/ja not_active Expired - Fee Related
- 2004-03-11 WO PCT/US2004/007540 patent/WO2004083203A1/en not_active Ceased
- 2004-03-11 DE DE602004024374T patent/DE602004024374D1/de not_active Expired - Lifetime
- 2004-03-11 AT AT04719833T patent/ATE450530T1/de not_active IP Right Cessation
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1311336A (en) * | 1970-09-07 | 1973-03-28 | Ici Ltd | Quaternary salts of pyrolylpyridine derivatives |
| WO1995018122A2 (en) * | 1993-12-30 | 1995-07-06 | Ciba-Geigy Ag | Heteroarylpyrroles |
| WO1996040634A1 (en) * | 1995-06-07 | 1996-12-19 | Nippon Shinyaku Co., Ltd. | Pyrrole derivatives and medicinal composition |
| WO1997016426A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| JPH10324687A (ja) * | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
| JP2000514808A (ja) * | 1997-06-16 | 2000-11-07 | ファイザー製薬株式会社 | インターロイキン―およびtnfアンタゴニストとして有用なピリジルピロール化合物 |
| JP2002544272A (ja) * | 1999-05-14 | 2002-12-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換3−ピリジル−4−アリールピロール並びに関連した治療及び予防法 |
| JP2001247564A (ja) * | 1999-07-21 | 2001-09-11 | Sankyo Co Ltd | ヘテロアリール置換ピロール誘導体 |
| JP2002284780A (ja) * | 2001-01-22 | 2002-10-03 | Sankyo Co Ltd | 4又は5置換ピロール誘導体 |
| WO2002064586A2 (en) * | 2001-02-09 | 2002-08-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of erk2 and uses thereof |
| WO2002079193A1 (en) * | 2001-03-29 | 2002-10-10 | Cyclacel Limited | Inhibitors of cyclin dependent kinases as anti-cancer agent |
| WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| WO2004029040A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases |
| WO2004056368A1 (en) * | 2002-12-19 | 2004-07-08 | Cyclacel Limited | Therapeutic applications of 2-substituted 4-heteroarylryrimidines |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004024374D1 (de) | 2010-01-14 |
| JP2006520386A (ja) | 2006-09-07 |
| AU2004221881A1 (en) | 2004-09-30 |
| WO2004083203A1 (en) | 2004-09-30 |
| EP1606284A1 (en) | 2005-12-21 |
| ATE450530T1 (de) | 2009-12-15 |
| CA2522176A1 (en) | 2004-09-30 |
| US7456190B2 (en) | 2008-11-25 |
| EP1606284B1 (en) | 2009-12-02 |
| US20040220200A1 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7456190B2 (en) | Compositions useful as protein kinase inhibitors | |
| USRE49500E1 (en) | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | |
| DE60214701T2 (de) | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen | |
| US7244735B2 (en) | Heterocyclic protein kinase inhibitors and uses thereof | |
| JP4741948B2 (ja) | プロテインキナーゼインヒビターおよびそれらの使用 | |
| JP4570955B2 (ja) | プロテインキナーゼ阻害活性を持つイミダゾール類 | |
| US20040097504A1 (en) | Compositions useful as inhibitors of jak and other protein kinases | |
| US7462612B2 (en) | Pyridine inhibitors of ERK2 and uses thereof | |
| US7314885B2 (en) | Pyrrole compounds useful as kinase inhibitors | |
| US8653088B2 (en) | Compositions useful as inhibitors of protein kinases | |
| JP2006518381A (ja) | プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール | |
| WO2006085685A1 (ja) | ピラゾール化合物 | |
| EP1603886A1 (en) | 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors | |
| WO2011041634A1 (en) | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070301 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100811 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100910 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110523 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110722 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110816 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140826 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |